BioCryst is constantly seeking to expand and improve its therapeutic development pipeline. It utilizes strategic partnerships early in the drug identification process through in-licensing of drug targets. BioCryst has also established collaborative relationships for the development and commercialization of product candidates to expand its geographic reach beyond the United States.
If you are interested in contacting BioCryst regarding partnering opportunities, please email the Business Development team at: businessdevelopment@BioCryst.com.
Torii Pharmaceutical, Co.
In November 2019, BioCryst announced that it had licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for ORLADEYO® (berotralstat) for the prevention of hereditary angioedema (HAE) attacks.
Shionogi & Co., Ltd.
In March 2007, BioCryst entered into an exclusive license agreement to develop and commercialize peramivir in Japan and Taiwan for the treatment of influenza. An intravenous formulation of peramivir has been marketed under the commercial name RAPIACTA® for the treatment of adults, children and infants with influenza since 2010.
Green Cross Corporation
In June 2006, BioCryst and Green Cross Corp. entered into an agreement to develop and commercialize peramivir in Korea. Green Cross Corp. announced in August 2010 that it had received marketing and manufacturing authorization for IV peramivir in Korea to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza.
In June 2021, BioCryst and Neopharm Ltd. in Israel entered into a distribution and supply agreement granting exclusive rights to commercialize ORLADEYO in Israel. Neopharm Ltd. is one of the leading pharmaceutical companies in Israel, providing the Israeli market with a wide range of products and integrated services.
In September 2021, BioCryst and NewBridge Pharmaceuticals entered into a distribution and supply agreement to commercialize ORLADEYO in the Gulf Cooperation Council (GCC) and Iraq. NewBridge is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize FDA or EMA approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.
In November 2011, BioCryst and Mundipharma amended their 2006 licensing agreement to grant Mundipharma exclusive worldwide rights to develop and commercialize forodesine in the field of oncology.
The University of Alabama at Birmingham
Albert Einstein College of Medicine of Yeshiva University